348 Studies Now Enrolling
Menu
Search
Status
Medical Condition
Displaying 1 - 3 of 3
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to determine the combination dose of patritumab deruxtecan and osimertinib that can be given to patients safely and to understand how well patritumab deruxtecan alone or in combination with osimertinib works to treat lung cancer. Osimertinib is an EGFR TKI therapy that targets EGFR mutations. Osimertinib has already been…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
The purpose of this study is to find out if the study drug, HE4 has the potential to improve performance of biomarker CA 125 to determine recurrence of epithelial ovarian cancer before detecting the cancer clinically, surgically or through radiological scans. HE4 (Human Epididymis Protein 4) is a biomarker expressed in the normal lining of the female…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
HE4 (Human Epididymis Protein 4) is a biomarker expressed in the normal lining of the female genital tract and breast. We are doing this research study to if HE4 is an indicator of treatment response during initial therapy for Primary Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancers. For this we will collect…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE